Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients

Basit Öğe Kaydı
dc.authorscopusid55327241300
dc.authorscopusid15019132000
dc.authorscopusid15019221400
dc.authorscopusid56610814100
dc.authorscopusid55754179900
dc.authorscopusid25230530900
dc.authorscopusid55600007800
dc.contributor.authorBal, Oznur
dc.contributor.authorArslan, Ulku Yalcintas
dc.contributor.authorDurnali, Ayse
dc.contributor.authorUyetrk, Ummugul
dc.contributor.authorDemirci, Ayse
dc.contributor.authorTastekin, Didem
dc.contributor.authorEkinci, Ahmet
dc.date.accessioned2024-09-25T19:43:10Z
dc.date.available2024-09-25T19:43:10Z
dc.date.issued2015
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractPurpose: To evaluate the impact of progesterone receptor (PR) status on estrogen receptor (ER)-positive and HER2-negative breast cancer. Methods: A total of 1673 operable breast cancer patients, diagnosed from June 1984 to June 2 Oil were retrospectively reviewed and 400 patients with ER-positive and HER2-negative tumors were identified and evaluated. ER-positive and HER2-negative patients were classified into two groups: group A: ER+/PR-/HER2- And group B : ER+/PR+/HER2- According to PR status. Results: Median follow-up was 14.2 years (range 10.1-18.2). The ratio of postmenopausal patients was significantly higher in group A (68.2%, p=0.015). Grade 1 tumor and stage I disease were significantly higher in group B (15%, p=0.007 and 15%, p=0.005, respectively). Mean overall survival (OS) and disease free survival (DFS) were significantly better in group B (15.3±1.5 years vs 8.7±0.8 years, p=0.032; 10.5±1.6 years vs 5.7±0.5 years, p=0.022) as compared with group A Relative risk for recurrence and death were two-fold higher in group A (p=0.05 and p=0.01, respectively). Conclusion: PR status exerts a significant impact on prognosis ofER+/HER2- breast cancer.en_US
dc.identifier.endpage34en_US
dc.identifier.issn1107-0625
dc.identifier.issue1en_US
dc.identifier.pmid25778292en_US
dc.identifier.scopus2-s2.0-84928696434en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage28en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12483
dc.identifier.volume20en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectBreast canceren_US
dc.subjectEstrogen receptoren_US
dc.subjectHER2en_US
dc.subjectProgesterone receptoren_US
dc.subjectPrognosisen_US
dc.titleProgesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu